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To date, genome-wide association studies (GWASs) have identified >100 loci with single variants associatedwith bodymass index
(BMI). This approach maymiss loci with high allelic heterogeneity; therefore, the aim of the present study was to use gene-based
meta-analysis to identify regions with high allelic heterogeneity to discover additional obesity susceptibility loci. We included
GWAS data from 123 865 individuals of European descent from 46 cohorts in Stage 1 and Metabochip data from additional 103 046
individuals from 43 cohorts in Stage 2, all within the Genetic Investigation of ANthropometric Traits (GIANT) consortium. Each
cohortwastested forassociationbetween∼2.4million (Stage 1) or∼200000 (Stage 2) imputed or genotypedsingle variants andBMI,
and summary statistics were subsequently meta-analyzed in 17941 genes. We used the ‘VErsatile Gene-based Association Study’
(VEGAS) approach to assign variants to genes and to calculate gene-based P-values based on simulations. The VEGASmethodwas
applied to each cohort separately before a gene-basedmeta-analysiswas performed. In Stage 1, two known (FTO and TMEM18) and
six novel (PEX2,MTFR2, SSFA2, IARS2, CEP295 and TXNDC12) loci were associated with BMI (P< 2.8 × 10−6 for 17 941 gene tests). We
confirmed all loci, and six of them were gene-wide significant in Stage 2 alone. We provide biological support for the loci by
pathway, expression and methylation analyses. Our results indicate that gene-based meta-analysis of GWAS provides a useful
strategy to find loci of interest that were not identified in standard single-marker analyses due to high allelic heterogeneity.
Introduction
Genome-wide association studies (GWASs) and large-scale colla-
borations have revolutionized the field of complex disease genet-
ics. Body mass index (BMI) is commonly used to assess obesity
and >100 loci have been discovered to date in studies of indivi-
duals of primarily European descent (1,2). Nevertheless, a large
proportion of the genetic variance remains undiscovered, imply-
ing that more loci influencing BMI are yet to be found (3). Add-
itional explanations for the missing heritability include, among
others, incomplete tagging of causal variants and allelic hetero-
geneity—multiple alleles in the same gene region that affect the
same trait (4,5). One approach to detect regions that display sub-
stantial allelic heterogeneity is to use gene-based tests of associ-
ation. Gene-based tests can improve statistical power in the
presence of allelic heterogeneity by combining single variants
from GWAS into a gene-based score, which substantially reduces
the burden of multiple testing and combines signals from mul-
tiple associated variants (6–8). One of severalmethodswhere sig-
nificance levels from single variant associations are used to
calculate a gene-based test statistic is the VErsatile Gene-based
Association Study (VEGAS) approach (8). VEGAS performs
equivalently to other gene-based approaches (8), but it is superior
to other methods when used in meta-analyses because it uses
external reference panels to simulate a null distribution, i.e. it
can be run with summary association statistics and does not re-
quire individual-level genotypic data.
A gene-based test can also improve the ability to replicate loci
displaying high between-study heterogeneity. Differences in the
underlying linkage disequilibrium (LD) patterns could lead to dif-
ferent tag single nucleotide polymorphisms (SNPs) being linked
to the causal variants in different study populations, a problem
that is lessened in gene-based tests as they are combined into
the same gene signal. Thus, using gene-based methods should
increase statistical power for GWAS regions with allelic and be-
tween-study heterogeneity, and applying these techniques
could implicate novel loci without increasing sample sizes or col-
lecting new data. Hence, the aims of the present study were (1) to
identify new loci associated with BMI and (2) to evaluate our
gene-based meta-analysis as a valid approach using a set of sen-
sitivity analyses and comparisons. Toward these aims, we used
existing GWAS data from the GIANT (Genetic Investigation of AN-
thropometric Traits) consortium. To enhance power by allowing
for allelic heterogeneity between studies, we applied the VEGAS
summary statistics algorithm on each GWAS study separately be-
fore combining the results in a single gene-based meta-analysis.
Results
Stage 1 identified six novel loci associated with BMI
We first analyzed the Stage 1 data set comprising 46 studies in-
cluding up to 123 865 individuals who had undergone GWAS of
BMI, as detailed elsewhere by Speliotes et al. (1). In brief, the
GWASwas done assuming an additive geneticmodel with inverse
normal transformation of BMI. The VEGASmethodwas applied to
each of the GWAS result files from the 46 studies individually, be-
fore a gene-based meta-analysis using the Fisher method was
conducted on 17 941 genes (Fig. 1; Supplementary Material,
Fig. S1). Each gene was defined with symmetric boundaries
±50 kb (the default in VEGAS); however, results from VEGAS are
in general robust across different gene boundaries chosen (9). A
SNP could contribute tomultiple gene signals if the genesare over-
lapping. Thus, a locus could includemultiple neighboring or over-
lapping genes that could partly rely on the same SNP signals.
Applying a Bonferroni-corrected gene-wide significance
threshold (P < 2.8 × 10−6 for 17 941 gene tests) for gene-based asso-
ciation with BMI, we identified six loci that have previously not
been implicated in relation to BMI (at least 1 Mb from published
genome-wide SNPs); the first locus contained four significant
genes in high LD (Supplementary Material, Fig. S2): thioredoxin
domain containing 12 (TXNDC12); KTI12 homolog, chromatin as-
sociated (KTI12); basic transcription factor 3-like 4 (BTF3L4) and
zinc finger, FYVE domain containing 9 (ZFYVE9). The other five
significant loci harboredonlyone gene each: peroxisomal biogen-
esis factor 2 (PEX2); mitochondrial fission regulator 2 (MTFR2);
sperm-specific antigen 2 (SSFA2); isoleucyl-tRNA synthetase 2
(IARS2) and centrosomal protein 295 kDa (CEP295), also known
as KIAA1731. In addition, two well-known BMI-associated loci
were confirmed in our analyses; the first locus contained the fat
mass- and obesity-associated gene (FTO) and the second locus
the gene transmembrane protein 18 (TMEM18). Details about
the associations are given in Table 1 and regional plots are
shown in Supplementary Material, Figure S3A–H.
Stage 2 validated the BMI loci found in Stage 1
In order to validate loci that reached gene-wide significance in
the Stage 1 analyses, we performed Stage 2 analyses in 43
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additional cohorts including 103 046 individuals with data
from the Metabochip array published in Locke et al. (2) using
the same gene-based approach (Fig. 1; Supplementary Mater-
ial, Fig. S1). The Metabochip array does not have a dense gen-
ome-wide coverage of SNPs; however, the gene coverage as
judged by the VEGAS results is almost as complete (17 833
genes in Stage 2 compared with 17 941 in Stage 1). Moreover,
analyzing the SNPs that contributed to the VEGAS signals
in Stage 1 showed that many SNPs were common between
Stages 1 and 2 (Supplementary Material, Fig. S4). Thus, all
eight loci replicated in Stage 2 with a significance well below
a Bonferroni-corrected threshold (α = 0.00625 for eight tests)
(Table 1).
Although replication of the significant genes was the primary
goal of Stage 2, we also report additional gene-wide significant
hits that arise when using these data to the full extent. Hence,
two loci, both previously established, including the genes mela-
nocortin 4 receptor (MC4R) and adenylate cyclase 3 (ADCY3), re-
spectively, were identified in Stage 2 alone (Table 1). Further, in
a joint Stage 1 + 2 analysis, in addition to all genes in the eight
loci from Stage 1, another five loci also reached the gene-wide
threshold andwas represented by the genes chromobox homolog
4 (CBX4), sperm associated antigen 6 (SPAG6), spastic paraplegia
11 (autosomal recessive) (SPG11), KH domain containing, RNA
binding, signal transduction associated 1 (KHDRBS1) and riboso-
mal protein L23a pseudogene 74 (RPL23AP74) (Table 1).
Figure 1.Workflowdescribing the process of gene-based analyses applied on the different data sets. The gene-basedmeta-analyses were carried out in a Stage 1material
of 46 different studies from the Speliotes et al. paper. Results were then validated in a Stage 2 phase including 43 studies from the MetaboChip in the Locke et al. paper
depicted in the figure. A joint gene-based meta-analysis of Stage 1 and Stage 2 data sets were subsequently done. The two right panels refer to the gene-based analyses
carried out of the summary statistics from Speliotes et al. and Locke et al. For clarity, the corresponding tables in the paper are illustrated in the figure.
Table 1. Gene-wide significant BMI-associated loci from gene-based meta-analyses of Stage 1, 2 and 1 + 2 data sets
Locus Gene Chr Position Stage 1 P-value Stage 2 P-value Stage 1 + 2 P-value
Start Stop
1 TXNDC12 1 52 258 391 52 293 635 1.3E−14 2.3E−14 5.5E−27
KTI12 1 52 270 364 52 272 060 1.2E−12 9.3E−13 2.0E−23
BTF3L4 1 52 294 560 52 326 650 1.8E−12 3.2E−12 9.7E−23
ZFYVE9 1 52 380 633 52 584 946 9.7E−07 1.5E−03 1.6E−08
2 PEX2 8 78 055 048 78 075 079 3.4E−13 1.7E−07 1.1E−18
3 FTO 16 52 295 375 52 705 882 1.6E−10 3.1E−13 1.1E−21
4 MTFR2 6 136 593 860 136 613 142 9.7E−08 4.5E−07 4.9E−13
5 TMEM18 2 657 972 667 439 1.8E−07 1.9E−08 4.8E−14
6 SSFA2 2 182 464 926 182 503 706 6.3E−07 3.1E−05 2.0E−10
7 IARS2 1 218 334 077 218 388 006 2.1E−06 1.1E−08 3.8E−13
8 CEP295 11 93 034 463 93 103 170 2.3E−06 8.1E−05 1.7E− 09
Additional gene-wide significant hits in Stage 2
9 MC4R 18 58 038 564 58 040 001 2.2E−03 6.4E−07 5.1E−08
10 ADCY3 2 25 042 038 25 142 055 2.2E−01 9.3E−07 5.5E−05
Additional gene-wide significant hits in Stage 1 + 2
11 CBX4 17 75 421 549 75 427 808 1.1E−05 3.9E−06 4.6E−10
12 SPAG6 10 22 674 404 22 746 545 3.9E−05 4.5E−05 1.6E−08
13 SPG11 15 42 642 185 42 743 168 2.4E−05 2.2E−04 4.5E−08
8 TAF1D 11 93 108 745 93 114 310 1.2E−04 5.2E−04 4.9E−07
14 KHDRBS1 1 32 252 077 32 282 059 2.0E−05 3.0E−03 5.5E−07
15 RPL23AP74 17 56 501 992 56 502 554 2.3E−04 7.5E−04 1.3E−06
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Pathway analyses of BMI-associated genes
Using data from Stage 1, we performed pathway analyses includ-
ing all genes with nominally significant (P < 0.05) association
with BMI (n = 773) using ConsensusPathDB (10). We observed an
enrichment for pathways disease (Q-value <0.003) and synthesis
of bile acids and bile salts via 24-hydroxycholesterol (Q-value <0.05).
Combining Stages 1 and 2, pathway analyses of the 942 top-
ranking genes (again P < 0.05 for association with BMI) revealed
enrichment in peptide hormone biosynthesis (Q-value <0.002), osteo-
pontin signaling (Q-value <0.004), glycoprotein hormones (Q-value
<0.004) and regulation of cytoplasmic and nuclear SMAD2/3 signaling
(Q-value <0.05).
We further performed pathway and network analysis using
Ingenuity software (11) (Qiagen, fall 2014 version) with the top
genes from the gene-based association analysis, also including
the established Stage 2 hits MC4R and ADCY3 to allow for a
more stable network. The most significant canonical pathway
was Glutathione Redox Reactions II, P = 1.96 × 10−3. The top network
not only involved FTO, MTFR2, ADCY3 and MC4R but also the
novel genes SSFA2 and ZFYVE9. The nuclear FTO was an import-
ant hub with many connections centrally regulating many of the
other genes (Fig. 2). Strikingly, one of these geneswas leptin (LEP),
a hormone known to be involved in obesity signaling (12). This
finding is especially interesting in the light of recent important
functional studies disentangling the causal variants and genes
in the FTO locus, which have highlighted not only IRX3 and
IRX5 (13,14) but also RPRIP1L (15) and FTO (16).
Gene expression analyses of identified genes
To provide biological support for and to further validate the BMI-
associated genes identified in Stage 1, we explored those genes in
relevant expression data sets. To accomplish this aim, we down-
loaded all data related to obesity from blood or adipose tissue in
human, mouse or rat found in the Gene Expression Omnibus
(GEO) data repository. All data sets were independently cross-
examined by two different investigators (S.H. and E.I.) and under-
went quality control steps before further inclusion. Altogether, 53
selected experiments including 335 obese cases and 308 controls
were finally used for analyses.
In each data set, although our primary goal was to test the
11 genes identified in Stage 1, all genes were screened for dif-
ferential expression between obese cases and controls, and
ranked by significance. This allowed for a null distribution to
be generated for each experiment by permuting the ranking
of the gene. We then evaluated if the 11 genes were signifi-
cantly deviating from the null distribution. Using a Bonferroni
correction (threshold P-value = 0.0045) for the 11 genes tested,
we found 2 genes (TXNDC12, P = 0.00021 and SSFA2, P = 0.00051)
to be significantly differentially expressed (having a lower rank
than expected based on the null) between obese cases and con-
trols in blood and adipose tissue combined (Fig. 3). As judged
from the heat map, both TXNDC12 and BTF3L4 from the same
loci with borderline significance of P = 0.0066 had higher gene
expression (positive fold change) in obese cases versus con-
trols in most of the studies, whereas SSFA2, on the contrary,
showed lower expression (negative fold change) in obese in
most studies.
Expression and methylation quantitative trait loci
analyses
To further investigate functional aspects of the loci identified in
Stage 1, we performed both expression quantitative trait loci
(eQTL) and methylation QTL (mQTL) analyses (Supplementary
Material, Table S7), including any SNPs from the loci identified
in Stage 1. Such analyses can identify functional SNPs further
emphasizing a role for certain genes in obesity development.
We analyzed the largest number of samples available for either
blood or adipose tissue, and additionally using a smaller data set
from carotid plaques. At first, we used the Genotype-Tissue Ex-
pression (GTEx) portal (17) to look for significant cis-eQTL asso-
ciations within 1 Mb window of the genes’ start/stop positions
in whole-blood samples (n = 168). We found four significant
cis-eQTLs (based on permutation) within the gene TXNDC12
(Supplementary Material, Fig. S5). Further, to calculate gene sig-
nificance from eQTL data, a gene-specific empirical P-value was
generated, and the corresponding Q-value for that gene was
calculated (where Q-value <0.05 is indicating significance). In
this analysis, the TXNDC12 gene was found to be significant
(Q-value = 0.0065).
Then,we further analyzed cis-eQTLs from adipose tissue (±1 Mb
gene boundaries) by the Genevar (GENe Expression VARiation)
platform (18) using default settings with P-value cutoff of
<0.001. The samples (n = 856) were collected from the TwinsUK
cohort with healthy females of European descent (19). Again,
TXNDC12 was found to have two significant eQTLs (Supplemen-
tary Material, Fig. S6), and from the same locus, ZFYVE9 had four
significant eQTLs from two different Illumina expression probes
(Supplementary Material, Fig. S7). Two other genes also revealed
significant eQTLs: PEX2 with 36 significant eQTLs (Supplemen-
tary Material, Fig. S8) and FTO with three significant eQTLs
(Supplementary Material, Fig. S9).
For the mQTL analyses, we again used the Genevar platform
to characterize all genes identified in Stage 1 in the same adipose
tissue samples from female twins (n = 856). The degree of DNA
methylation at specific CpG sites was assessed by the Illumina
HumanMethylation450 bead chip. The maximum distance to
probe start was set to 0.1 Mb, and the P-value cutoff level was
<0.001. We found strong enrichment of cis-mQTLs in the locus
of the PEX2 gene; two different CpG sites were identified, which
were associatedwith 28 and 82mQTLs, respectively (Supplemen-
tary Material, Fig. S10). The FTO gene also showed strong enrich-
ments of multiple cis-mQTLs. We found six different CpG sites to
be enriched, with 26, 23, 16, 16, 30 and 83 mQTLs, respectively
(Supplementary Material, Fig. S11). Lastly, we found five CpG
sites with significant SNPs within TMEM18. Again, the enrich-
ment was very strong in at least four of the five sites and all to-
gether, we identified 41, 17, 9, 38 and 101 mQTLs, respectively
(Supplementary Material, Fig. S12).
Finally, we decided to do mQTL follow-up analyses, including
association tests with BMI of identified cis-mQTLs (13 CpGs from
PEX2, FTO and TMEM18) in participants of the Dutch Athero-
Express cohort using carotid plaque (N = 488) and blood (N = 92)
samples. All three genes had at least one significant mQTL in pla-
ques (Supplementary Material, Table S1 and Fig. S13) and in blood
(Supplementary Material, Table S2 and Fig. S13), when adjusting
formultiple testing using false discovery rate (FDR < 0.05). Methy-
lation levels in plaques at the promoter-associated cg01780754 lo-
cated within the PEX2 gene, a probe that was significant in all
tissue-specific mQTL analyses, was also significantly associated
with BMI (FDR-adjusted P-value = 0.009). Specifically, our data
show that the C allele of rs9643429 located upstream of PEX2 (in
LD with the best mQTL SNP) is linked to higher methylation at
cg01780754 in plaques, andwhenmethylated, cg01780754 is asso-
ciated with an increase in BMI. The combined functional effects
found for PEX2 is summarized in Supplementary Material,
Figure S14.
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Evaluation of our gene-based meta-analysis approach
As a secondary aimof this study,we anticipated to evaluate other
possible approaches that could have been undertaken, as well as
investigating plausible biases from using VEGAS. Our a priori
hypothesis was that performing gene-based analyses in each
individual study as we did would be a more efficient approach
to pick up additionally unknown loci, likely by catching more al-
lelic and between-study heterogeneity, than an approach where
gene-based analysis was applied once to the summary statistics
from the meta-analysis of SNP-based results. To test this
Figure 2. The gene network createdwith the nuclear gene FTO at center, directly and indirectly regulating the other genes in this network. Ingenuity softwarewas used to
establish a genenetwork including the top genes identified in Stage 1 and Stage 2 analyses of the gene-basedmeta-analyses. Thenetwork involvednot only the genes FTO,
MTFR2, ADCY8 and MC4R but also the genes SSFA2 and ZFYVE9. The nuclear FTO was found to be one of the hubs in the network together with the well-established BMI
gene LEP.
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assumption empirically, we performed VEGAS gene-based ana-
lysis on the summary statistics of the single-SNP meta-analysis
of BMI by Speliotes et al. (1), which included 123 865 individuals
from 43 studies (Fig. 1). The gene-based analysis based on the
summary statistics generated a list of 20 significant loci, corre-
sponding to 59 genes, all of which have been reported in the ori-
ginal publication (Supplementary Material, Table S3). We then
compared the loci identified in our Stage 1 analysis with this
gene-based analysis of the summary statistics from Speliotes
et al. and found that none of the newly identified loci were
gene-wide significant (Supplementary Material, Table S4) in the
latter analysis, whereas the previously established loci (FTO and
TMEM18) were represented among the top findings, reaching
gene-wide significance.
The same approach was undertaken to examine the gene-
based analysis of the summary statistics data from Locke et al.
(2), which was the data source used for our Stage 2 analyses
(Fig. 1). The result from the VEGAS analysis revealed 33 gene-
wide significant loci containing 110 genes in total (Supplemen-
tary Material, Table S5). All gene-wide significant loci, except
for two, were already reported as being associated with BMI in
the Locke et al. paper. The two newly identified loci were golgin
A2 (GOLGA2) and secretory carrier membrane protein 4
(SCAMP4). When we then compared these results with the
gene-based loci identified in our Stage 1, the only common loci
were again the established ones (FTO and TMEM18) (Supplemen-
tary Material, Table S6). Thus, our hypothesis that applying the
VEGAS software on summary statistics would render fewer
novel loci compared with our approach of performing VEGAS in
each substudy before meta-analyzing seemed to be true. The
most likely reason for this observation is that allelic heterogen-
eity in the gene-based meta-analysis (Stage 1 and 2 results),
wheremany different SNP signals rather than a strong single dri-
ver, gave rise to the gene-wide significant hits. This explanation
was further supported by the variety of top SNPs that contributed
to the VEGAS gene-based signals in Stages 1 and 2 (Supplemen-
tary Material, Figs S3 and S4). However, there is yet to be proven
if the novel BMI loci are good biological targets.
Next,wedecided to investigatewhether the length of the gene
could bias our observed results. The VEGAS method corrects for
the number of SNPs within each gene and also for gene length
as has been shown before (20). Nonetheless, using Stage 1 data,
themean gene length of all geneswas 70 582 bp,whereas theme-
dian gene length was 28 333 bp (range: 2 304 483 bp), indicating a
skewed distribution. At first, we analyzed the mean gene length
of a varying list of top genes (P < 10−6 to P < 0.05 for inclusion)
comparingwith the rest of the genes, but foundno significant dif-
ferences (Table 2). However, as the top gene list increased when
relaxing the P-value threshold evenmore, there was a significant
difference inmean gene length between the groups, with shorter
genes among the top genes indicating that VEGAS tends to over-
adjust for gene length (Table 2). To further support this notion,
we performed correlation analysis and found a weak but signifi-
cant correlation between increased gene length and higher
P-value (Spearman rank ρ = 0.14; P < 10−16).
Finally, we performed sensitivity analyses in the three most
promising novel loci (PEX2, TXNDC12 and SSFA2) in Stage 1 co-
horts. For each locus and cohort, we deleted the best SNP as re-
ported by VEGAS and consequently reran VEGAS on all data
sets. The difference in the gene-based P-value from the two
runs (with and without the best SNP) in each cohort and locus
is presented in Supplementary Material, Figure S15. The mean
difference in gene-based P-value in each cohort (PSensitivity −
PNormal) was 0.015 for PEX2, 0.020 for SSFA2 and 0.022 for
TXNDC12. The overall conclusion when summing up the Fisher
χ2 statistics over all cohorts was that the final gene-based
P-value changed one 10-fold to the higher for all three loci, still
well below gene-wide detection for PEX2 and TXNDC12, and
reaching borderline significance level for SSFA2.
Discussion
In this study, we present a novel approach utilizing previous
GWAS results by applying gene-based methods on individual
study results followed by meta-analysis in order to find new
loci associated with BMI. The study samples used were all from
the GIANT consortium including Stage 1 (1) and Stage 2 data
(2). We identified six new loci associated with BMI, including sev-
eral genes with high potential for further functional follow-up
studies (e.g. PEX2, TXNDC12 and SSFA2), and could confirm two
established loci (FTO and TMEM18). All loci were replicated in
Figure 3. Gene expression validation of genes identified in Stage 1. We
downloaded expression data from obese individuals/mice/rats in whole blood
or adipose tissue from the GEO repository to look for differential expression of
the 11 genes found in Stage 1. Using a rank-based permutation method to
generate the null distribution, we concluded that the genes TXNDC12 and SSFA2
were significantly differentially expressed between obese cases and controls
using a Bonferroni-corrected threshold of 0.0045. The color bar describes the
log2 fold change value for each gene in each study, where blue represents lower
expression and red higher expression in obese cases versus controls.
Table 2. Gene length in relation to P-value fromVEGASmeta-analysis
P-value cutoff N Mean gene length (bp) P-valuea
Top genes Top genes Other genes
<E−6 10 90 603 70 571 0.65
<0.00001 10 90 603 70 571 0.65
<0.0001 16 73 688 70 582 0.51
<0.001 31 59 548 70 612 0.47
<0.01 145 54 417 70 772 0.23
<0.05 530 49 916 71 489 0.06
<0.10 1007 46 644 72 655 0.0052
<0.15 1479 46 391 73 789 3.3E−05
<0.20 1967 46 228 75 072 8.4E−08
<0.30 2912 46 576 77 771 4.8E−12
<0.40 3934 46 818 81 326 4.3E−22
<0.50 4922 49 233 84 205 3.0E−24
<0.60 5982 50 339 88 783 9.8E−29
<0.70 7180 51 681 95 459 1.6E−34
<0.80 8487 52 974 106 608 5.2E−45
<0.90 9972 55 084 128 585 3.8E−57
at-Tests were done on the logarithm of gene length because of the skewed
distribution.
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Stage 2, andwe provide further biological support from a range of
bioinformatics approaches, such as expression analyses, as well
as pathways, and eQTL and mQTL analyses (Supplementary
Material, Table S7).
The concept of allelic heterogeneity
Allelic heterogeneity occurs when multiple alleles in the same
locus are associated with the same trait. The phenomenon of al-
lelic heterogeneity is being reported for more and more loci and
traits, and it is a well-known phenomenon in long-established
loci, such as BRCA1 and BRCA2. It is easy to imagine several causal
variants that affect the same gene transcripts through changes in
expression levels or gene structure and function, and thereby in
the end affect the same biological mechanism. Loci that display
high allelic heterogeneity can be missed by conventional GWAS
of individual variants, as the statistics are based on one variant
at the time. Gene-based methods on the other hand combine
all signals for individual variantswithin the same gene to a single
gene-based signal, hence accounting for allelic heterogeneity.
Moreover, by applying a gene-based meta-analysis on the
study-level data (instead of performing the analyses on the
meta-analysis summary statistics), the allelic heterogeneity is
better accounted for, and moreover, between-study heterogen-
eity is captured if existing. By comparing the results of the
gene-based analysis done on a cohort level (Table 1) with a
gene-based analysis based on summary statistics (Supplemen-
tary Material, Tables S3 and S5), we could conclude that very dif-
ferent set of genes are being identified using the two approaches.
Thus, this observation supports our notion that the heterogen-
eity is more accurately picked up by VEGAS when run on cohort
level data rather than directly on the GWAS meta-analysis sum-
mary data. The likely reason is that all SNPs and cohorts contrib-
ute to the result, not just a single significant SNP in a large cohort,
a suggestion that is further supported by the replication in Stage 2
(Table 1), sensitivity analyses without the best SNP (Supplemen-
tary Material, Fig. S15) and the variety of lead SNPs from different
studies in the significant loci (Supplementary Material, Figs S3
and S4).
In performing a gene-based association test, one presumes
that the contributions of different causal variants will be asso-
ciated with the outcome via the same downstream disease
mechanism. However, an important feature in Fisher’s method
for meta-analysis is that it allows effect sizes in both positive
and negative directions, so there is no restriction in the types of
allelic heterogeneity within the gene.
Multivariatemethods where independent SNPs are combined
within the same locus have improved the total variance ex-
plained, suggesting that allelic heterogeneity could be a major
contributor (4,5). However, independent SNP signals within a
locus are often difficult to identify because standard GWASs are
not designed to do so and there are computational limitations
of multivariate studies. On the contrary, the gene-based ap-
proach has the potential to detect loci where independent SNP
signals contribute to the same gene-based signal. Thus, loci
with strong secondary signals are prioritized, and as a conse-
quence, we identified some of the established BMI loci with
known secondary signals among our top findings. FTO and
TMEM18 (identified in Stage 1), as well as MC4R (identified in
Stage 2), have been reported to harbor multiple SNPs associated
with BMI (21).
The loci with allelic heterogeneity are also more likely to con-
tain functional SNPs, as judged by software such as PolyPhen and
by eQTLmapping (4,5). In light of this, it is not surprising that the
QTL investigations in this study concluded that 5 of the 11 genes
(4 of the 8 loci) that we discovered in Stage 1 showed evidence of
enrichment in eQTLs and/or mQTLs (Supplementary Material,
Table S7). When also considering the expression and pathway
analyses, we found functional evidence in 7 of the 11 genes
(6 of the 8 loci) (Supplementary Material, Table S7).
VEGAS in comparison with other gene-based methods
There is a growing number of gene-based bioinformatics tools
available. Many of them use participant-level genotype data as
input, perform a gene-based association test using permutations
and summarize the results in a list of gene-to-trait associations
(6,22). These methods usually perform well in terms of limiting
false-positive rates; however, they have a great disadvantage
being computationally demanding and needing access to partici-
pant-level genotype data, which usually is impossible in the set-
ting of large genetic consortia. Other methods, including VEGAS,
only use a list of SNP P-values as input and then consider the
underlying SNP–SNP correlation pattern using HapMap Project’s
genotype data or other data sources (7,8,23). These methods are
computationally less burdensome and use summary result
files, which is crucial when working within large international
consortia.
The method in VEGAS that we used performs well compared
with other gene-based analyses considering different gene
boundaries (9). Basically, VEGAS is stable across different bound-
aries chosen and remains powerful even with the inclusion of
non-significant SNPs (9). We used the default gene boundary in
VEGAS (±50 kb), which is appropriate as GWAS hits are enriched
within this distance (24).
GWASs are known to prioritize SNPs in the close vicinity to or
within genes of long length (20,24). The VEGASmethod, however,
has been shown to compensate for the gene length bias in the
analysis (20). Our study investigated this further and found that
VEGAS tends to be too stringent when compensating for gene
length, and as a consequence, long genes are less likely to be sig-
nificant. The fact thatwe did not identify any genes related to be-
havior and appetite, which are usually found in genetic studies of
BMI, could be a result of this phenomena, as brain genes tend to
be longer than other genes (25).
Functional aspects of newly identified genes
The protein encoded by TXNDC12 is characterized by a conserved
active motif called the thioredoxin fold that catalyzes disulfide
bond formation and isomerization (26). The txndc12 knockout
model in mice does not show any phenotype changes. However,
a study in grouper fish concluded that TXNDC12 is an important
antioxidant with potential physiological properties (27). They
further noticed that it is predominately expressed in liver,muscle
and brain, and in addition, we found it to be differentially ex-
pressed in both blood and adipose tissue (which they did not
test). Another interesting candidate gene from the same locus
is ZFYVE9, which encodes a double zinc finger protein that inter-
acts with SMAD proteins that are signal transducers in the trans-
forming growth factor β (TGF-β) signaling pathway. The relation
to TGF-β is also demonstrated in the network analysis (Fig. 2). A
mediated knockdown model of zfyve9a in zebrafish inhibits the
formation of the liver in early embryogenesis (28). In addition,
we found significant eQTLs in adipose tissue strengthening the
functional aspect of this gene. The four genes located in this
locus at Chromosome 1 are found in a region with strong LD
(Supplementary Material, Fig. S2). Using VEGAS, we cannot
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compensate for including the same SNPs in several genes; thus,
many SNPs are common between genes in a region like this (Sup-
plementary Material, Fig. S16). Based on the functional data we
present, TXNDC12 seems to be the best candidate for involve-
ment in adiposity among the four, followed by ZFYVE9 that also
had some functional validation and did not share any of the
most strongly associated BMI SNPs with TXNDC12.
The protein encoded by PEX2 belongs to a family of peroxi-
somal membrane proteins where gene mutations lead to peroxi-
some biogenesis disorders, such as Zellweger syndrome with
various abnormalities seen in the central nervous system (29).
The pex2 knockout mouse dies before weaning at ∼13 days of
age, which is in line with humans suffering from the Zellweger
syndromewhousually die at adolescence. Decreased levels of tri-
glycerides and high-density lipoprotein cholesterol in plasma are
seen before dying (30), and PEX2 has also been shown to decrease
angiogenesis in ischemia and wound healing (31). We found sig-
nificant eQTLs in the PEX2 locus and strong enrichment of
mQTLs in adipose tissue, carotid plaques and blood. Moreover,
DNA methylation in carotid plaques was associated with BMI,
indicating an intrinsic SNP–methylation–obesity relationship
(Supplementary Material, Fig. S14). Thus, we highlight a func-
tional role of PEX2 through gene expression and in particular
methylation in multiple tissues.
SSFA2was first considered a cancer-related gene as its expres-
sion level is altered in colon cancer cells (32), but other findings
have described its role inmetabolic disturbances through regula-
tion of energy homeostasis and the exocrine system with impli-
cations for obesity and diabetes (33–36). SSFA2 is expressed in
brown adipose tissue, liver, pancreas, stomach and kidney. The
ssfa2 gene knockoutmousemodel exhibit decreased bodyweight
and adipose tissue, resistance to diet-induced obesity and in-
creased food intake and metabolic rate. Moreover, abnormal glu-
cose homeostasis and hormone levels are detected (33,36) and it
is connected to LEP in the gene network (Fig. 2). Our gene expres-
sion analysis further concluded that SSFA2 is associated with
obesity (Fig. 3).
The MTFR2 gene is not well known but is involved in aerobic
respiration in the mitochondria. The Ingenuity analysis high-
lighted MTFR2 in the cytoplasm where it is regulated by nuclear
genes important for obesity (Fig. 2). IARS2 encodes a tRNA
synthetase for isoleucine found in mitochondria. Isoleucine is
the predominant amino acid in human mitochondria and small
changes of the aminoacylation propertiesmay be of great import-
ance (37). Pointmutations found in this gene have been shown to
cause fatal cardiomyopathy, growth retardation, hearing defi-
ciency, neuropathy and skeletal dysplasia (38,39). CEP295, also
called KIAA1731, is a putative centrosomal protein containing
an ALMS motif, also seen in the gene Alström syndrome 1
(ALMS1). As the name imply, mutations in ALMS1 cause Alström
syndrome, a rare progressive condition characterized by neuro-
sensory degeneration and metabolic defects (40).
Strengths and limitations
Amain strength of this studywas the very large sample size used
for the VEGAS analyses, and that we could do gene-based ana-
lyses in each participating study before meta-analyzing (instead
of using the summary statistics from the meta-analysis to do
gene-based analyses). Our approach allowed for the identifica-
tion of six novel loci associated with BMI. Moreover, as no new
samples were interrogated in this study, this approach highlights
the potential of the gene-based meta-analysis method as such
for reuse of existing data. The soundness of this approach was
confirmed by replication of all loci in an independent validation
stage (Stage 2) as well as by confirmation of well-known BMI
GWAS loci with documented strong secondary signals (FTO,
TMEM18 and MC4R). Furthermore, by using pathway analyses,
gene expression data and eQTL and mQTL analyses, we were
able to functionally validate genes in six of eight loci found.
This also illustrates the possibility of using VEGAS to prioritize
among candidate GWAS genes as the top genes from VEGAS are
more likely to harbor functional variants.
Limitations of the study include the assumptions needed for
the gene-based analysis, such as the one-directional effect size. It
is also worth mentioning that the VEGAS method could be run
with other settings, for example using a different LD panel,
which would most likely render slightly different results. We fur-
ther concluded that VEGAS overadjusts for gene length, which
may have had an impact on the results. Moreover, the functional
validation of the significant geneswas only concentrated to those
specific genes; no additional genes in the close vicinity were con-
sidered to limit the extent of multiple testing; hence, further
functional studies arewarranted to concludewhether the identi-
fied genes are truly linked to obesity. The gene expression ana-
lysis was restricted to blood and adipose tissue as these were
the tissues frequently available in the GEO repository; investigat-
ing brain tissue in relation to obesity status would most likely
have rendered a different result. Finally, as all results are based
on analyses of individuals of European descent, the generaliz-
ability to other ethnicities is unknown.
Conclusions
In this study, we present a novel approach for conducting gene-
based meta-analysis to reutilize large GWAS data sets in order
to identify new genes involved in complex diseases. Moreover,
we perform extensive bioinformatic functional validation of the
identified genes illustrating the potential of using methods like
VEGAS to prioritize among candidate genes and to detect loci
with high allelic heterogeneity. Using this approach, we highlight
several new promising gene candidates for further validation in
functional studies, such as TXNDC12, PEX2 and SSFA2. Further at-
tempts using gene-basedmeta-analyses of existing data for other
phenotypes using the methods outlined are encouraged.
Materials and Methods
Study samples
The Stage 1 data set comprised 46 studies with in total 123 865
individuals of European descent. The sample sizes varied from
276 to 26 799 individuals per study, and they were genotyped
using Affymetrix or Illumina technology as described elsewhere
(1). BMI levels were inverse normally transformed and adjusted
for age, age2 and study-specific covariates such as population
stratification by principal components. All genotype data were
imputed to the HapMap CEU panel and badly imputed SNPs
(r̂2 < 0:3 in MACH, observed/expected dosage variance <0.3 in
BimBam or proper_info <0.4 in IMPUTE), and those with a
minor allele count <6 per cohort-specific strata were removed.
Analysis using additive models for association between geno-
type and BMI was performed on cohort level, and each GWAS
was then corrected with lambda genomic control. For the
meta-analysis on individual-variant level, the inverse variance
method in METAL software was used [analyses performed as
previously reported (1)].
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The Stage 2 data set included 43 additional studies of Euro-
pean ancestry with genotype data available from the Illumina
iSelect Metabochip, the only additional data available to us for
replication at the time of analysis, covering 196 725 SNPs selected
for cardiac and metabolic phenotypes, including 5055 SNPs se-
lected for associations with BMI (2). The Metabochip data were
not imputed, but corrected with lambda genomic control in
each study separately.
The VEGAS method
To yield lists of gene-based P-values for associationwith BMI, the
VEGAS software (http://gump.qimr.edu.au/VEGAS/) was applied
to each cohort separately. The VEGAS algorithm has been de-
scribed elsewhere (8), but in brief, it takes the full set of markers
within a gene and accounts for LD by simulations from HapMap
LD structures. A gene-based test statistic is calculated as the sum
of all χ2-converted SNP P-values within that gene. The null distri-
bution is then calculated using Monte Carlo simulation taking
into account the LD structure that results in a large number of
multivariate normal vectors with the same distribution as our
gene-based test statistic. The simulation approach is computa-
tionally faster than using permutations but performs equally
well (8). The assignment of SNPs to genes was done with the
UCSC genome browser hg18 assembly rendering 17 941 genes.
Gene boundaries were defined as ±50 kb of 5′ and 3′ untranslated
regions, which is the default setting in VEGAS. However, a study
investigating different boundaries in relation to the gene-based
result in several methods found the VEGAS sum method to be
stable for different lengths chosen (9). To limit the computational
burden, we set themaximumnumber of simulations to 1 000 000,
meaning that the lowest P-value that could be estimated was
1 × 10−6. The rationale for this number of simulations was the
Bonferroni-corrected gene-wide significance threshold of P < 2.8
× 10−6 (correcting for 17 941 gene tests). Due to this truncation, the
P-values from this gene-based approach appear higher than
those from single variant-based GWAS for some cohorts (for
example, for the FTO locus).
Meta-analysis using Fisher’s method
In gene-based association analysis, an underlying assumption is
that all causal effects within a gene are having the same direc-
tion. Therefore, when performing a meta-analysis on gene
level, a one-sided χ2 distribution as used in the Fisher method






Enrichment analysis for pathwayswas carried out using theweb-
based tool ConsensusPathDB (10) (http://cpdb.molgen.mpg.de/
CPDB/). Genes were searched for overrepresentation among dif-
ferent pathways, and Q-values were calculated from corrected
P-values using FDR from the hypergeometric distribution. In-
genuity Pathway Analysis (Qiagen, fall 2014 version) was used
for visualizing and analyzing the gene-based results of BMI (11).
We only focused on genes available in the Ingenuity Knowledge
Base. The confidencefilterwas set to consider only experimental-
ly observed direct and indirect relationships inmice, rats and hu-
mans. A maximum of 35 nodes per network and a maximum of
25 networks were generated. Ingenuity calculates the signifi-
cance values for canonical pathways by Fisher’s exact test right
tailed.
Gene expression analysis methods
Data sets for functional validation of the BMI-associated genes
from Stage 1 were identified in GEO (http://www.ncbi.nlm.nih.
gov/geo/) using the following search term: (‘blood’ OR ‘adipose
tissue’) AND (‘adiposity’ OR ‘obesity’ OR ‘obese’ OR ‘body-mass
index’ OR ‘body mass index’ OR ‘BMI’) AND (Homo sapiens
[Organism] OR Mus musculus[Organism] OR Rattus norvegicus
[Organism] AND (gds[Entry Type] OR gse[Entry Type])), which
rendered 322 hits. Two investigators (S.H. and E.I.) went through
the list independently and selected those data sets that fulfilled
the criteria of having obese cases versus non-obese controls
within similar experimental settings. The final number of data
sets that were selected via consensus for further analysis was
76. The data sets were downloaded from the GEO repository
using R with the GEOquery package and analyzed using the
limma package. Each data set could sometimes be split intomul-
tiple subsets depending on experimental designs, e.g. mouse
models with different time intervals, as long as the case–control
criteria were met. All data sets were quantile normalized and
log2-transformed if not done already, and quality control of the
final differential analysiswas done using volcano plots. Bad qual-
ity data, microRNA-chip data and lack of control samples were
common reasons for exclusions of data sets during the analysis
procedure. The final data set included 335 cases and 308 controls
from 53 experiments. Differential expression analysis was con-
ducted within each experiment, and the transcript with the low-
est P-value within the same gene, if multiple transcripts existed,
was selected. Geneswere compared between different array plat-
forms using the official human HGNC gene symbol list down-
loaded from NCBI. All gene aliases and orthologous genes in
mouse and rat were consequently translated to the official
human symbol and accounted for in the search. Every gene in
each data set was then ranked according to P-value, and the
final rank was scaled to the same distribution (rank = position/
number_of_genes). The average ranking for each genewas calcu-
lated across all 53 data sets where missing genes in any data set
were assigned the rank 0.5. To calculate the null distribution,
each data setwas permuted 300 times and the average gene rank-
ing was computed 300 times for each gene. Then, the 300 per-
muted gene ranks were compared with the original gene rank
for each gene separately to generate a P-value. The final P-value
was further Bonferroni corrected taking 11 tests into account for
the 11 genes tested.
QTL methods
Enrichments of QTL were tested using three approaches. First,
the GTEx portal (17) (http://www.gtexportal.org/home/) was
used via their web interface for screening of eQTLs in whole
blood. Expression data were collected from Affymetrix arrays or
Illumina RNA sequencing, and genotype data from Illumina ar-
rays. We only tested for cis-eQTLs allowing SNPs to reside in a
window of 1 Mb from start or stop of the corresponding gene.
The overall enrichment significance for a gene was calculated
with FDR using permutation and presented in an adjusted
Q-value. The number of significant cis-eQTLs within each gene
was dependent on the permutation-based P-value threshold for
that gene. The samples (n = 168) used for whole-blood analysis
were collected through the Cancer Human Biobank (caHUB) of
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the National Cancer Institute and came from adult individuals of
any sex and ancestry, taken either during surgery or postmortem.
Specifications on sample quality or data preprocessing can be
found online. The second software used for QTL analyses was
the Genevar platform (18) (http://www.sanger.ac.uk/resources/
software/genevar/) developed at the Wellcome Trust Sanger In-
stitute. The software is a standalone Java application, which
was downloaded to the computer and once running, it connects
to the online databases needed. Again, we defined cis-eQTLs as
SNPs within ±1 Mb of gene boundaries and used the default set-
tings for significance with cutoff for P-value <0.001. The corre-
sponding numbers for the cis-mQTLs were ±0.1 Mb gene
boundaries and a P-value cutoff level <0.001. The Genevar soft-
ware does not present any overall gene scores as GTEx does.
The samples were from adipose tissue collected from the Twin-
sUK cohort with 856 healthy female twins of European descent
run on Illumina HumanMethylation450 bead chip (19,41).
Lastly, mQTL analyses were performed in Athero-Express, a
cohort including patients from two Dutch hospitals undergoing
carotid endarterectomy. DNA was isolated from carotid artery
plaque samples of 500 patients and ethylenediaminetetraacetic
acid whole-blood samples of 100 matched patients and checked
for purity and concentration using a Nanodrop system (Thermo
Scientific, Massachusetts, USA). DNA concentrations were equal-
ized, bisulphate converted and used to measure DNA methyla-
tion using the HumanMethylation450 bead chip (Illumina, San
Diego, USA), according to the manufacturer’s protocol. Data
were processed using the ‘MethylAid’ in R (42) with normaliza-
tion and batch-effect correction using ‘Functional Normalization’
with eight principal components of control probes. Invariable
probes (β range: 0–0.1 and 0.9–1) and outliers at >3 SD from me-
dian were removed from each probe. After quality control, 488
plaque samples, 92 blood samples and 443 872 probes (41 640
probes were excluded) remained for further analysis. Genotyp-
ing, available in 444 plaques and 92 blood samples, has previ-
ously been performed and is described elsewhere (43). For the
association with BMI, linear regression modeling was performed
with covariates age and sex. mQTL analysis was performed
in SNPtest (v2.5) using a model with covariates age, sex and
SNP array type. The Benjamini–Hochberg method was used to
account for multiple testing, where a FDR <5% was considered
statistically significant.
Gene length analyses
The information on gene length was extracted and downloaded
from the table browser at UCSC Genome Browser website. The
genes were sorted based on significance from the VEGAS Stage
1 analysis, and the top genes were compared with the comple-
mentary gene list using different cutoff values (P < 10−6, <10−5,
<0.0001, <0.001, <0.01, <0.05, <0.10, <0.15, <0.20, <0.30, <0.40,
<0.50, <0.60, <0.70, <0.80, <0.90). A two samples t-test was used
in the calculation and applied to the log-transformed values of
gene lengths due to the skewed distribution of gene length. In
addition, a Spearman rank correlation test between gene length
and P-value was performed.
Sensitivity analyses
The best SNP as judged from the lowest P-valuewithin each gene
is reported by VEGAS for each individual cohort. The stability of
the gene-based P-value can be investigated if the best SNP is de-
leted from the data set. Consequently, for each of the three loci
(PEX2, TXNDC12 and SSFA2), the best SNP as reported for each
cohort and locus was deleted and VEGAS analysis was again
undertaken. The difference between the originally reported
gene-based P-value and the newly generated gene-based P-
value (without the best SNP in the data set) was calculated and
evaluated.
Statistical software
The VEGAS software was used in an offline command version
and additional analyses were carried out using Unix, Perl, R
3.0.0 or 3.1.1 and Mathematica version 8. The LD pattern plot
was created using SNAP software version 2.2 (SNP Annotation
and Proxy Search; http://www.broadinstitute.org/mpg/snap/
ldplot.php) with SNP data set 1000 Genomes Pilot 1 and popula-
tion panel CEU. The union of all SNPs contributing to the gene-
based signal from the TXNDC12 locus with four genes
(TXNDC12, BTF3L4, KTI12 and ZFYVE9) was submitted (n = 90
SNPs). Regional plots were made by the Locus Zoom online web
tool (http://csg.sph.umich.edu/locuszoom/) where SNPs contrib-
uting to the gene-based signals and the corresponding P-value
from each GWAS were uploaded for each locus separately. The
best SNP in the locus was chosen for each cohort, and if several
cohorts had the same SNP, it was plottedmultiple times. The ref-
erence panel was 1000 Genomes build hg18 with population
panel CEU.
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